By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL
One of the presentations I attended during this year’s annual JPM Conference was that of Sage Therapeutics, a company we featured in our July 2018 issue (“Sage Therapeutics — Sitting On The Brink Of CNS Breakthroughs”). I briefly met Sage’s CEO, Jeff Jonas, M.D., after his presentation, to thank him in person for sharing his company’s story with our readers. I had enjoyed my interviews with Jonas, not only for his candor but also because of my interest in Sage’s therapeutic area of focus — depression.